Inari Medical, Inc. stock is currently trading at USD 79.97, resting near its 52-week high of USD 79.99. The company’s market capitalization stands at approximately USD 4.68 billion, indicating strong investor confidence in the medical device manufacturer. This update matters because the stability in price and volume suggests consistent market interest without significant volatility in recent sessions.
Company Overview
Inari Medical, Inc. is a healthcare company specializing in medical devices. It develops, manufactures, markets, and sells products for the interventional treatment of venous diseases. Its key product lines include the ClotTriever mechanical thrombectomy system for deep vein thrombosis and the FlowTriever aspiration and thrombectomy system for pulmonary embolism treatment.
The company also offers FlowSaver, FlowStasis, and the newer FlowTriever 2, reflecting ongoing product innovation aimed at improving patient outcomes. Founded in 2011 and headquartered in Irvine, California, Inari Medical transitioned from its former name Inceptus Newco1 Inc. in 2013.
Stock Performance
As of the latest data, NARI shares are priced at USD 79.97, with no recorded change from the prior session, translating to a 0% change percentage. The stock’s range over the past year spans USD 36.73 to USD 79.99, placing it at the upper limit and underscoring a period of strength.
Trading volume for the session stands at 2,356,692 shares, close to the average volume of 2,438,930 shares. This consistency suggests steady market activity without unusual spikes or drops in trading interest. For investors, such stability can be a sign of sustained sentiment and reduced volatility risk.
Market Position and Sector
Inari Medical operates in the Medical Devices segment of the Healthcare sector. Within this framework, the company focuses on the niche of venous disease treatment where mechanical thrombectomy devices are increasingly recognized as effective solutions.
The market capitalization of USD 4.68 billion places Inari Medical well above small-cap territory, providing it with greater access to capital and visibility. The sector overall is characterized by high regulation and the need for continuous innovation, giving competitive advantage to companies with strong R&D pipelines.
Governance and Leadership
Kevin Strange leads as Chief Executive Officer. Under his direction, the company has expanded its product portfolio and maintained growth since its IPO in May 2020. Governance in medical technology firms requires balancing compliance with agencies such as the FDA while pursuing faster product iterations. Leadership stability is key for maintaining investor confidence.
Key Financial Data
Investors examining NARI should note:
- Price: USD 79.97 – signals proximity to 52-week high
- Market Cap: USD 4,683,331,092 – mid-to-large cap range supports liquidity
- Dividend: No dividend (last dividend 0) – funds are retained for growth or reinvestment
- 52-week Range: USD 36.73 to USD 79.99 – highlights upward trajectory
- Volume: 2,356,692 shares – consistent with average volume
The lack of dividend may indicate a strategy focused on growth via reinvestment rather than income distribution. Market cap and range figures point to a company that has exhibited strong appreciation over the recent year.
FAQ
- Does Inari Medical pay a dividend? No. The last recorded dividend was 0 USD per share.
- Where is Inari Medical traded? Shares trade on the NASDAQ Global Select exchange.
- What are its identifying security codes? ISIN: US45332Y1091, CUSIP: 45332Y109.
- When was the IPO? The company listed on May 22, 2020.
- How many employees does Inari Medical have? Approximately 1,300 full-time employees.
Conclusion
Inari Medical’s stock performance currently reflects strong positioning in the market, with prices near their annual highs and volumes holding steady. The company’s focus on specialized medical devices for venous diseases, combined with consistent leadership, keeps it attractive to healthcare-focused investors. Growth strategies and regulatory compliance will continue to define its competitive standing.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research or consult qualified professionals before making any investment decisions.
Official Announcement
For full information about the company, see the link below.